Key result
A planned systematic review and network meta-analysis will evaluate the comparative efficacy of ACEI/ARB, aldosterone receptor antagonists, and statins in preventing atrial fibrillation recurrence.
Why the study?
Atrial fibrillation carries significant morbidity, mortality, and health burden, prompting the need to assess the comparative effects and safety of non-antiarrhythmic drugs in preventing AF recurrence.
Do ACEI/ARB, aldosterone receptor antagonists, and statins prevent recurrence of atrial fibrillation in patients with paroxysmal or persistent AF?
Systematic Review
Do ACEI/ARB, aldosterone receptor antagonists, and statins prevent recurrence of atrial fibrillation in patients with paroxysmal or persistent AF?
This protocol outlines a planned network meta-analysis to evaluate the comparative efficacy of upstream therapies (ACEI/ARB, MRAs, statins) for preventing atrial fibrillation recurrence.
Answers are grounded in this paper and cite their sources.
Supports upstream RAAS blockade or statins to curb AF recurrence; extends pairwise data with comparative efficacy rankings.
BACKGROUND: Atrial fibrillation (AF) is one of the most common arrhythmias, and is high relative to cardiovascular morbidity and mortality. AF-related complications and treatment costs bring about huge health burden, therefore the prevention recurrence of AF is imperative. "Upstream therapy" refers to the use of non-antiarrhythmic drugs (non-AADs) that modify the atrial substrate or target-specific mechanisms of AF to prevent the occurrence or recurrence of the arrhythmia. RAAS Blockers, aldosterone receptor antagonists and statins have an effect on preventing recurrence of atrial fibrillation. This protocol is designed for systematic review and network meta-analysis, which will assess comparative effects and safety of various non-antiarrhythmic drugs in preventing recurrence of atrial fibrillation. METHODS: The Cochrane Library, MEDLINE, EMBASE, ClinicalTrials.gov will be searched from inception to Aug 31, 2020 to identify relevant studies. The Cochrane "Risk of bias" tool will be used to assess the methodological quality of eligible studies. The pair-wise meta-analysis will be performed by STATA 14.0 software. The network meta-analysis will be implemented in a Bayesian framework using Win BUGS 1.4.3 and the package "gemtc" V.0.8.1 of R-3.6.2 software. The network plots will be drawn using STATA 14.0 software. A comparison-adjusted funnel plot will be used to assess the publication bias using STATA 14.0 software. Quality of evidence will be assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. RESULTS: The results of this network meta-analysis will determine the preventive effect and rank ordering of these interventions for recurrence of AF. The report will follow the PRISMA checklist for network meta-analysis. CONCLUSION: This network meta-analysis will provide comprehensive evidence-based information in clinical practice. INPLASY REGISTRATION NUMBER: INPLASY202090004.
No takes yet. Share an insight, caveat, or question.
Jia et al. (2021) conducted a systematic review in Atrial fibrillation. ACEI/ARB, aldosterone receptor antagonists, and statins vs. Placebo or no drug combined with standard therapy was evaluated on Time to a first electrocardiographically confirmed recurrence of atrial fibrillation. A planned systematic review and network meta-analysis will evaluate the comparative efficacy of ACEI/ARB, aldosterone receptor antagonists, and statins in preventing atrial fibrillation recurrence.
Synapse has enriched 10 related papers. Consider them for comparative context: